| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
IDO1 protein levels are dose-dependently decreased by NU223612 (0.1–10 μM; 24 hours) [1]. The concentration of NU223612 (the point at which 50% of IDO1 protein is broken down) in GBM43 and U87 cells was found to be 0.5438 μM and 0.3290 μM, respectively [1]. Several cell types, including human pancreatic cancer cells CD18 and PANC-1, ovarian cancer cells OVCAR5 and SKOV3, prostate cancer cells PC3, and syngeneic GL261 mice expressing IDO1 cDNA (IDO1-O/E)) Glioma cell lines, can be treated with NU223612 to breakdown IDO1 protein[1]. Moreover, NU223612 decreased the amounts of IDO1 protein in the human GBM cells' cytoplasm and intranuclear compartments. Subcellular spaces can be penetrated by NU223612 [1]. In cultured IFNγ-stimulated GBM cells, NU223612 dose-dependently inhibits IDO1 enzymatic activity, leading to decreased Kyn levels. IDO1 non-enzymatically mediated NF-κB p65 transcription factor DNA binding activity and IDO1-mediated tryptophan metabolism are inhibited by NU223612 [1].
|
|---|---|
| ln Vivo |
NU223612 (25 mg/kg; i.p.; once) decreases IDO1 protein in GL261 cells C57BL/6 expressing mIDO1 cDNA [1]. NU223612 (25 mg/kg; i.p.; 5 days/week; for 3 weeks) enhances median overall survival and long-term survival up to 45 days after tumor cell injection [1]. Mass spectrometry study of NU223612 (25 mg/kg; i.p.; once) indicated a Cmax of 2 μM in brain tissue and a half-life of 8.3 hours. In plasma, Cmax is 365 μM and half-life is 2.5 hours. NU223612 was mixed with mouse brain homogenate using 6 hours of equilibrium dialysis, and the findings showed that the binding rate of NU223612 was 99.8%[1]. Half-life, AUC and Cmax of NU223612 in serum and brain samples[1]. Plasma brain half-life (h) 2.5 8.3 AUC0-24 (μM▪h) 582 7 Cmax (μM) 365 2
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: U87 and human GBM43 Cell Tested Concentrations: 0 μM, 0.1 μM, 1 μM and 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: IDO1 protein levels were diminished in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice carrying GL261 cells [1]
Doses: 25 mg/kg Route of Administration: intraperitoneal (ip) injection; Experimental Results: IDO1 protein was diminished by >70% within 2 hrs (hrs (hours)) after treatment and remained low for up to 24 hrs (hrs (hours)). Animal/Disease Models: 8weeks old C57BL/6 wild-type (WT) mice were intracranially transplanted with luciferase-modified GL261 cells (GL261-luc.) [1] Doses: 25 mg/kg Route of Administration: intraperitoneal (ip) injection; weekly 5 days; lasts 3 weeks Experimental Results: Results in increased median overall survival and long-term survival up to 45 days after tumor cell injection. |
| References |
| Molecular Formula |
C49H55FN6O9
|
|---|---|
| Exact Mass |
890.401
|
| CAS # |
2759420-43-2
|
| PubChem CID |
166176927
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
65
|
| Complexity |
1670
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1C=CC2C(C=1)=C(C=CN=2)C1CCC([C@H](C(NC2C=CC(=CC=2)OC2CCN(C(CCOCCOCCNC3=CC=CC4C(N(C(C=43)=O)C3C(NC(CC3)=O)=O)=O)=O)CC2)=O)C)CC1
|
| InChi Key |
PLYOHMQINGIYDN-LVMIGYEDSA-N
|
| InChi Code |
InChI=1S/C49H55FN6O9/c1-30(31-5-7-32(8-6-31)37-17-21-51-40-14-9-33(50)29-39(37)40)46(59)53-34-10-12-35(13-11-34)65-36-18-23-55(24-19-36)44(58)20-25-63-27-28-64-26-22-52-41-4-2-3-38-45(41)49(62)56(48(38)61)42-15-16-43(57)54-47(42)60/h2-4,9-14,17,21,29-32,36,42,52H,5-8,15-16,18-20,22-28H2,1H3,(H,53,59)(H,54,57,60)/t30-,31?,32?,42?/m1/s1
|
| Chemical Name |
(2R)-N-[4-[1-[3-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]propanoyl]piperidin-4-yl]oxyphenyl]-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
